)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Ekso Bionics
Ekso Bionics (EKSO) investor relations material
Ekso Bionics has been acquired by Applied Digital Corp
Ekso Bionics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary10 Jul, 2026
Company overview and business model
Operates through two subsidiaries: Applied Digital Cloud Corporation (cloud services for AI/ML developers) and Ekso Bionics, Inc. (exoskeletons for healthcare), with plans to divest the exoskeleton business and focus solely on cloud services by Q1 2027.
Cloud business provides energized colocation space and equipment for AI/ML workloads, with revenue currently concentrated in a single customer, Together AI.
Recent business combination and holding company restructuring resulted in a new parent entity, with all shareholders maintaining their ownership percentage.
Financial performance and metrics
Cloud business reported net losses of $72.7M for FY ended May 31, 2025, and $32.8M for the nine months ended Feb 28, 2026.
Legacy Ekso business reported net losses of $11.7M for FY ended Dec 31, 2025, and $6.9M for the three months ended Mar 31, 2026.
Issued 700,000 shares for $4.6M in warrant exercises in May 2026; 355,961 shares issued upon Series B Preferred Stock conversion.
Use of proceeds and capital allocation
No proceeds from the resale of shares by selling stockholders; company will only pay registration-related fees and expenses.
Net proceeds from recent private placements were $3.2M (Oct 2025) and $5.3M (Jan 2026), used for general corporate purposes.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ekso Bionics
- AI cloud infrastructure firm divesting legacy business, registering shares for resale with no proceeds.EKSO
Registration filing - Q1 2026 revenue dropped 37% and net loss deepened, with liquidity concerns and major dilution risk ahead.EKSOQ1 2026
- AI-powered exoskeletons and CMS reimbursement fuel rapid growth in neuro-rehabilitation.EKSOInvestor presentation
- Record Q4 revenue, improved margins, and narrowed annual net loss highlight operational progress.EKSOQ4 2025
- Business combination creates ChronoScale, with APLD Investors gaining control and new governance.EKSOProxy Filing
- Registration of 10.5M shares for resale highlights dilution and Nasdaq delisting risks.EKSORegistration Filing
- Net loss narrowed and CMS reimbursement milestone achieved, but liquidity remains a concern.EKSOQ3 2024
- Record sales and improved margins set the stage for growth, but funding risks persist.EKSOQ2 2024
- Record Q4 revenue, improved margins, and new partnerships position for 2025 growth.EKSOQ4 2024
Ekso Bionics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ekso Bionics Holdings Inc. is a company that develops and manufactures wearable exoskeletons designed to enhance human mobility and strength. Its core products include robotic exoskeletons used in rehabilitation and industrial applications. In healthcare, Ekso Bionics provides solutions that help patients with neurological conditions or injuries to regain mobility through assisted walking. The company's exoskeletons are also used in industrial settings to reduce worker fatigue and prevent injuries by augmenting human strength and endurance during heavy lifting and repetitive tasks. The company is headquartered in Richmond, California, USA, and its shares are listed on the NASDAQ.